Individualized Physical Activity and Carotid Plaque Instability

Carotid Atherosclerosis Clinical Trial

— PACAPh  

Official title:

Effect of an Individualized Home-based Physical Activity Trial on Carotid Plaque Vulnerability for Asymptomatic Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04053166
• Other study ID #: 69HCL19_0345
• Secondary ID: 2019-A01543-54
• Status: Completed
• Phase: N/A
• Start date: December 3, 2019
• Est. completion date: September 21, 2022

Study information

• Verified date: November 2022
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Intraplaque hemorrhage (IPH) is one of the main features of the carotid plaque instability's and predictor of ischemic stroke. Benefits (on the basis on benefit/risk ratio) of the carotid endarterectomy remain unclear for stroke asymptomatic patients; thus, more and more patients with important stenosis (i.e. over 60%) detected are not operated. However, these patients need adapted therapeutic treatments to limit plaque instability and this should include physical activity (PA). Indeed, PA has been showed to decrease numerous inflammatory markers involved in atherosclerosis. It has also recently been reported on stroke asymptomatic patients that the prevalence of carotid IPH was decreased in those with higher level of PA. Magnetic Resonance Imaging (MRI) of the IPH has been shown to be the better non-invasive imaging technique to assess carotid plaque instability and in particular IPH. Here, the aim of this study is to assess the effect of an individualized home-based 6 months physical activity intervention on carotid IPH and other biomarkers of vulnerability for asymptomatic patients. This study has been designed as a monocentric, longitudinal and interventional study. This study will involve one centre: Hopital Louis Pradel (HCL, Lyon). After inclusion tests, patients will be randomly included in the control group, or in the PA group. Patients of the PA group will have connected bracelets to measure daily count of steps. Twice a month, daily goals will be revaluated to increase or maintain the steps per day. The final goal is to reach 6 000 steps per day or increase by 30% the initial count of steps per day. Same tests will be done after 6 months of intervention for comparison.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: September 21, 2022
• Est. primary completion date: September 12, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient with an carotid atheromatous plaque with = 50% North American Symptomatic Carotid Endarterectomy Trial (NASCET) stenosis
• Patient from vascular surgery department of the Louis Pradel Hospital of the Hospices Civils de Lyon, but not operated
• Males and females aged over 18 years old
• No contra-indication to physical activity with index performance (PS) < 2
• Available and voluntary to invest in the study throughout its duration (6 months)
• Able to understand, read and write French;
• a social security system or similar;
• Having dated and signed informed consent.

Exclusion Criteria:

• Transient ischemic attack (TIA) or ipsilateral cerebral infarction less than 6 months
• History of ipsilateral carotid surgery or cervical irradiation;
• Cancer, heart failure, seropositivity;
• Coronary risk;
• Renal failure (Cockcroft clearance of creatinine < 30 milliliter/minute (mL/min);
• Contraindication and precautions for use related to Prohance: hypersensitivity to the active substance or to any of the constituents of Prohance, renal insufficiency with clearance <30 ml / min / 1.73 m², probability of convulsions during the higher examination in patients with epilepsy or brain injury, pregnancy, breastfeeding;
• Contraindication to MRI: ferromagnetic material (including pacemaker, implantable defibrillators, cardiac valve prostheses, cochlear implants, neurostimulators, implanted automated injection equipment, intraocular metallic foreign bodies, neurosurgical and vascular clips);
• Carotid occlusion;
• ipsilateral intracranial stenosis;
• Risk of pregnancy or proven pregnancy on interrogation data. Breastfeeding;
• Patient under guardianship, under curatorship or safeguard of justice;
• inability to express consent;
• uncontrolled cardiological or neurological diseases;
• Impossibility of being followed for medical, social, geographical or psychological reasons throughout the duration of the study.

Related Conditions & MeSH terms

• Atherosclerosis
• Carotid Artery Diseases
• Carotid Atherosclerosis

Intervention

Device:
• individualized home-based physical activity
Subjects will have to reach a daily goal in number of steps, based on the initial evaluation, during 6 months . They will wear connected wrists, and will be contacted twice a month by phone call by an adapted physical activity to revaluate these goals.

Other:
• MRI
An MRI will be performed for each patient at the end of the study to identify IPH and other features of histological vulnerability (lipid core, fibrous cap integrity and calcifications).

Biological:
• blood sampling
Blood will be collected, to analyse monocyte phenotype by flow cytometry, blood rheology by ektacytometry, coagulation by rotational thromboelastometry (ROTEM). Plasma will be extracted from blood to assess inflammation, oxidative stress and antioxidant markers.

Other:
• Questionnaires
sedentary, physical activity, nutrition and quality of life questionnaire will be performed fo each patient.
• 6-minute walk test
The 6-minute walk test is a simple, individualized test that measures how fast a patient walks on a flat, hard surface for 6 minutes.

Locations

Country	Name	City	State
France	Hôpital Louis Pradel	Bron

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	decreased intensity of IPH levels measured by MRI	Image quality will be assessed from 1 to 5 (grade 1, low Signal-to-Noise Ratio (SNR) limits use, arterial wall and vessel margins are unidentifiable; grade 2, marginal SNR, arterial wall is visible, but the substructure, lumen, and outer boundaries are indistinct; grade 3, marginal SNR, wall structures are identifiable, but lumen and outer boundaries are partially obscured; grade 4, high SNR with minimal artifacts, vessel wall, lumen, and adventitial margins are well defined; and grade 5, high SNR without artifacts, wall architecture depicted in detail, lumen and adventitial boundary are clearly defined) . If the quality of the image is sufficient (= 3), IPH levels will be semi-quantified on a scale from 0 to 3 (0: No IPH, 1: light IPH, 2 moderate IPH, strong IPH). Images will be assessed blindly and independently by clinical experts of carotid plaque imaging.	Day 0
Primary	decreased intensity of IPH levels measured by MRI	Image quality will be assessed from 1 to 5 (grade 1, low Signal-to-Noise Ratio (SNR) limits use, arterial wall and vessel margins are unidentifiable; grade 2, marginal SNR, arterial wall is visible, but the substructure, lumen, and outer boundaries are indistinct; grade 3, marginal SNR, wall structures are identifiable, but lumen and outer boundaries are partially obscured; grade 4, high SNR with minimal artifacts, vessel wall, lumen, and adventitial margins are well defined; and grade 5, high SNR without artifacts, wall architecture depicted in detail, lumen and adventitial boundary are clearly defined) . If the quality of the image is sufficient (= 3), IPH levels will be semi-quantified on a scale from 0 to 3 (0: No IPH, 1: light IPH, 2 moderate IPH, strong IPH). Images will be assessed blindly and independently by clinical experts of carotid plaque imaging.	Month 6
Secondary	Evaluation of intermediate monocyte phenotype (cluster of differentiation 14 (CD14)++ /cluster of differentiation 16 (CD16)+)	monocytes will be extracted from blood sample, marked with specific antibodies (anti CD14/16) and intermediate phenotypes (in %) will be measured by flow cytometry	Day 0
Secondary	Evaluation of intermediate monocyte phenotype (cluster of differentiation 14 (CD14)++ /cluster of differentiation 16 (CD16)+)	monocytes will be extracted from blood sample, marked with specific antibodies (anti CD14/16) and intermediate phenotypes (in %) will be measured by flow cytometry	Month 6
Secondary	Evaluation of classical monocyte phenotype (cluster of differentiation 14 (CD14)++ /cluster of differentiation 16 (CD16)-)	monocytes will be extracted from blood sample, marked with specific antibodies (anti CD14/16) and classical phenotypes (in %) will be measured by flow cytometry	Day 0
Secondary	Evaluation of classical monocyte phenotype (cluster of differentiation 14 (CD14)++ /cluster of differentiation 16 (CD16)-)	monocytes will be extracted from blood sample, marked with specific antibodies (anti CD14/16) and classical phenotypes (in %) will be measured by flow cytometry	Month 6
Secondary	Evaluation of non-classical monocyte phenotype (cluster of differentiation 14 (CD14)+ /cluster of differentiation 16 (CD16)++)	monocytes will be extracted from blood sample, marked with specific antibodies (anti CD14/16) and non-classical phenotypes (in %) will be measured by flow cytometry	Day 0
Secondary	Evaluation of non-classical monocyte phenotype (cluster of differentiation 14 (CD14)+ /cluster of differentiation 16 (CD16)++)	monocytes will be extracted from blood sample, marked with specific antibodies (anti CD14/16) and non-classical phenotypes (in %) will be measured by flow cytometry	Month 6
Secondary	Assessment of red blood cell aggregation	Red blood cell aggregation (in %)will be measured by ektacytometry	Day 0
Secondary	Assessment of red blood cell aggregation	Red blood cell aggregation (in %) will be measured by ektacytometry	Month 6
Secondary	in vitro clotting formation time	In vitro clotting formation time (in minutes) will be measured on whole blood by rotational thromboelastometry	Day 0
Secondary	in vitro clotting formation time	In vitro clotting formation time (in minutes) will be measured on whole blood by rotational thromboelastometry	Month 6
Secondary	Measurement of in vitro clot lysis index	In vitro clot lysis index (in millimeter) will be measured on whole blood by rotational thromboelastometry	Day 0
Secondary	Measurement of in vitro clot lysis index	In vitro clot lysis index (in millimeter) will be measured on whole blood by rotational thromboelastometry	Month 6
Secondary	Measurement of in vitro clot firmness	In vitro clot firmness (in millimeter) will be measured on whole blood by rotational thromboelastometry	Day 0
Secondary	Measurement of in vitro clot firmness	In vitro clot firmness (in millimeter) will be measured on whole blood by rotational thromboelastometry	Month 6
Secondary	Assessment of plasma lipid oxidation	Plasma protein oxidation (advanced oxidation proteins products) measured by by spectrophotometry (in micromole/liter (µmol/L))	Day 0
Secondary	Assessment of plasma lipid oxidation	Plasma protein oxidation (advanced oxidation proteins products) measured by by spectrophotometry (in micromole/liter (µmol/L))	Month 6
Secondary	Assessment of plasma protein oxidation	Plasma protein oxidation (advanced oxidation proteins products) measured by by spectrophotometry (in micromole/liter (µmol/L))	Day 0
Secondary	Assessment of plasma protein oxidation	Plasma protein oxidation (advanced oxidation proteins products) measured by by spectrophotometry (in micromole/liter (µmol/L))	Month 6
Secondary	Assessment of plasma protein nitration	Plasma protein nitration (nitrotyrosine) measured by the enzyme-linked immunosorbent assay (ELISA) in micromole/liter (µmol/L).	Day 0
Secondary	Assessment of plasma protein nitration	Plasma protein nitration (nitrotyrosine) measured by the enzyme-linked immunosorbent assay (ELISA) in micromole/liter (µmol/L).	Month 6
Secondary	Assessment of plasma inflammatory markers	Plasma inflammatory markers will be measured by multiplex assay in micromole/liter (µmol/L).	Day 0
Secondary	Assessment of plasma inflammatory markers	Plasma inflammatory markers will be measured by multiplex assay in micromole/liter (µmol/L).	Month 6
Secondary	Assessment of plasma enzymes activity	Plasma antioxidant enzymes activity will be measured by enzymology (in micromole/liter/minute (µmol/L/min))	Day 0
Secondary	Assessment of plasma enzymes activity	Plasma antioxidant enzymes activity will be measured by enzymology (in micromole/liter/minute (µmol/L/min))	Month 6
Secondary	number of steps per day	the daily number of steps (in number of step per day) will be measured using a connected wrist activity tracker	during 2 weeks after Day 0
Secondary	number of steps per day	the daily number of steps (in number of step per day) will be measured using a connected wrist activity tracker	during 2 weeks after Month 6
Secondary	distance of the 6 minutes walking test	The distance at the 6 minutes walking test (in meters) will be evaluated on the 30meters flat round-trip	Day 0
Secondary	distance of the 6 minutes walking test	The distance at the 6 minutes walking test (in meters) will be evaluated on the 30meters flat round-trip	Month 6
Secondary	quadriceps maximal isometric strength	The quadriceps maximal isometric strength (in Newton) will be evaluated in sitting position using dynamometer	Day 0
Secondary	quadriceps maximal isometric strength	The quadriceps maximal isometric strength (in Newton) will be evaluated in sitting position using dynamometer	Month 6
Secondary	Determination of the level of physical activity	the level physical activity will be evaluated by the global physical activity questionnaire (in Metabolic Equivalent of Task/minutes per week (MET/min.week)).	Day 0
Secondary	Determination of the level of physical activity	the level physical activity will be evaluated by the global physical activity questionnaire (in Metabolic Equivalent of Task/minutes per week (MET/min.week)).	Month 6
Secondary	Determination of the sedentary time	Sedentary time will be evaluated by the sedentary behaviour questionnaire evaluating the total daily sitting and lying down time (in minute/day) during awaking time.	Day 0
Secondary	Determination of the sedentary time	Sedentary time will be evaluated by the sedentary behaviour questionnaire evaluating the total daily sitting and lying down time (in minute/day) during awaking time.	Month 6
Secondary	descriptive health state score	Health state score will be assessed using descriptive system of the EQ-5D-5L (five-level version of the EuroQol five-dimensional) questionnaire.; Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The subjects self-rate their level of severity for each dimension using a five-level (EQ-5D-5L) scale (scored from 1 to 5, 1 indicating no problem and 5 indicating extreme problem).; The health rate score correspond to the addition of each dimension score and is from 5 to 25. The lower the score, the better the health state.	Day 0
Secondary	descriptive health state score	Health state score will be assessed using descriptive system of the EQ-5D-5L (five-level version of the EuroQol five-dimensional) questionnaire.; Health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The subjects self-rate their level of severity for each dimension using a five-level (EQ-5D-5L) scale (scored from 1 to 5, 1 indicating no problem and 5 indicating extreme problem).; The health rate score correspond to the addition of each dimension score and is from 5 to 25. The lower the score, the better the health state.	Month 6
Secondary	self-evaluated overall health status	Overall health status will be assessed using the evaluation part of the EQ-5D-5L (five-level version of the EuroQol five-dimensional) questionnaire.; The subject's self- evaluate their overall health status using the visual analogue scale (EQ-VAS).; The raw score is from 0 to 100. The higher the score, the better the perceived overall health status	Day 0
Secondary	self-evaluated overall health status	Overall health status will be assessed using the evaluation part of the EQ-5D-5L (five-level version of the EuroQol five-dimensional) questionnaire.; The subject's self- evaluate their overall health status using the visual analogue scale (EQ-VAS).; The raw score is from 0 to 100. The higher the score, the better the perceived overall health status	Month 6
Secondary	body mass index	Body mass index (in kilogram/metre² (kg/m²)) will be calculated with the measurement of body weight (in kilogram) and height (in meter)	Day 0
Secondary	body mass index	Body mass index (in kilogram/metre² (kg/m²)) will be calculated with the measurement of body weight (in kilogram) and height (in meter)	Month 6
Secondary	number of comorbidities	Number of comorbidities (Diabetes, hypertension, obesity and , poly-atheroma) will be determined	Day 0
Secondary	number of comorbidities	Number of comorbidities (Diabetes, hypertension, obesity and , poly-atheroma) will be determined	Month 6